| 64407 | |
| Combinations of glycopeptides and glycoproteins are used in the diagnosis, treatment, and monitoring of diseases and their causes in clinical, diagnostic, and discovery medicine. With some exceptions, current tests generally lack the necessary sensitivity and specificity for early and accurate diagnosis. Researchers at Purdue University have proposed an application of glycoprotein technology that greatly increases the specificity and sensitivity of serum tests for many types of cancer and other diseases. This novel method is used for stable isotope labeling and affinity selection of glycopeptides to identify serum glycoprotein changes. In addition to diagnosing and monitoring diseases, this method may also uncover novel targets for the development of therapeutics. Advantages: -Sensitive enough to detect cancers without biomarkers -Less complex and more sensitive than other methods Potential Applications: -Medical/Healthcare -Pharmaceuticals -Drug development -Drug targeting and screening |
|
|
|
|
Jun 30, 2008
Utility Patent
United States
8,568,993
Oct 29, 2013
Jun 30, 2008
PCT-Patent
WO
(None)
(None)
Jul 2, 2007
Provisional-Patent
United States
(None)
(None)
Feb 22, 2006
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
